Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in severe maternal outcome potentially related to treatment (death,… compared with placebo (outcomes (low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in mode of birth (caesarean section)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in postpartum haemorrhage** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
2 findings from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to lower severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Death (fetal, neonatal, or later (up to school age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to school age))** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Maternal anaemia · pregnant women
It is very uncertain whether summary of findings table ‐ Vitamin B12 supplementation changes maternal anaemia compared with placebo/no vitamin B12 supplementation (very low certainty).
1 finding from 1 review
Maternal vitamin B12 deficiency · pregnant women
It is very uncertain whether summary of findings table ‐ Vitamin B12 supplementation changes maternal vitamin B12 deficiency compared with placebo/no vitamin B12 supplementation (very low certainty).
1 finding from 1 review
Miscarriage and spontaneous abortion · pregnant women
1 finding from 1 review
Low birthweight · pregnant women
Summary of findings table ‐ Vitamin B12 supplementation showed no clear difference in low birthweight (< 2500 g) compared with placebo/no vitamin B12 supplementation (low certainty).
1 finding from 1 review
Preterm birth · pregnant women
Summary of findings table ‐ Vitamin B12 supplementation showed no clear difference in preterm birth (< 37 weeks) compared with placebo/no vitamin B12 supplementation (low certainty).
1 finding from 1 review
Child cognitive outcomes · pregnant women
1 finding from 1 review
Neural tube defects ‐ not reported · pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infant hospitalisation with laboratory‐confirmed RSV disease · pregnant women
Respiratory syncytial virus vaccine leads to lower infant hospitalisation with laboratory‐confirmed RSV disease compared with placebo (high certainty).
1 finding from 1 review
Infant hospitalisation with clinically confirmed RSV disease · pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found